• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Manufacturing
    • Packaging
    • Development
    • Compliance
    • Top 20
    • Directory
    • Microsites
    • Events
    • More
  • Magazine
  • News
  • Manufacturing
  • Packaging
  • Development
  • Compliance
  • Top 20
  • Directory
  • Microsites
  • Events
  • Current / Back Issue
    Features
    Editorial
    Columns
    Digital Edition
    eNewsletter Archive
    Our Team
    Editorial Guidelines
    Subscribe Now
    Advertise Now
    Top Features
    Biotechnology’s Role in Improving Stroke Outcomes

    CEO Spotlight: Marc Kikuchi

    Newsmakers: Darren Shirley

    Are You Prepared for the 2023 DSCSA Deadline?

    Rethinking the Changing Role of the CRO
    Breaking News
    Online Exclusives
    Industry News
    Collaborations & Alliances
    Promotions & Moves
    Trials & Filings
    Financial Reports
    Bio News & Views
    Custom Sourcing News
    Packaging & Tracking
    CRO News
    Live From Shows
    Top News
    BioIVT Acquires Scottish Drug-metabolizing Enzyme Manufacturer Cypex

    Schott Creates Stand-Alone Company for its Pharma Business

    Marken to Acquire Medical Courier Business of Cedra Express

    Porton’s New Crystallization and Drug Product Facility

    Thermo Fisher Expands NY Cell Culture Media Manufacturing Site
    APIs
    Aseptic Processing
    Cleaning Validation
    Clinical Trial Materials
    Cytotoxics and High Potency Manufacturing
    Equipment
    Excipients
    Extractables and Leachables
    Facilities
    Fill/Finish
    Lyophilization
    Parenterals
    Process Development
    Process Validation
    Risk Management
    Scale-up/ Technology Transfer
    Solid Dosage/ Creams/ Ointments

    Marken to Acquire Medical Courier Business of Cedra Express

    Porton’s New Crystallization and Drug Product Facility

    Thermo Fisher Expands NY Cell Culture Media Manufacturing Site

    Woodstock Sterile Solutions Fills Two Leadership Roles

    SmartLabs To Open New Facility in Philadelphia
    Capsules
    Cold Chain Management
    Injectables
    Logistics
    Serialization
    Solid Dosage / Semi-solids
    Supply Chain
    Vials

    Marken to Acquire Medical Courier Business of Cedra Express

    5 Key Features of Agile Pharmaceutical Packaging Supply Chains That Drive Results

    Novavax Expands Manufacturing Agreement with SK bioscience

    Lonza Continues to Lead the Market with Innovative Hard Empty Capsules

    Sharp Expands Reach to China Through Partnership with ClinsChain
    Analytical Services
    Bioanalytical Services
    Bioassay Developement
    Biologics, Proteins, Vaccines
    Biosimilars
    Chemistry
    Clinical Trials
    Drug Delivery
    Drug Development
    Drug Discovery
    Formulation Development
    Information Technology
    Laboratory Testing
    Methods Development
    Microbiology
    Preclinical Outsourcing
    R&D
    Toxicology

    Thermo Fisher Expands NY Cell Culture Media Manufacturing Site

    Thorne HealthTech, AstraZeneca Entend AI Discovery Alliance

    Gilead Sciences to Acquire MiroBio for $405M

    Amgen to Acquire ChemoCentryx for $3.7B

    BioNTech, Genmab Expand Global Strategic Oncology Collaboration
    Filtration & Purification
    GMPs/GCPs
    Inspections
    QA/QC
    Regulatory Affairs
    Validation

    Chime Biologics Receives Commercial Manufacturing License

    Automation Is Key to Meeting Demands in Pharmacovigilance

    UBC Acquires Examoto

    Responding to Consumer Complaints While Working with CMOs

    WuXi Vaccines Receives GMP Certificate from HPRA
    Companies
    Categories
    Corporate Capabilities
    Add New Company
    Contract Service Directory Companies
    Aphena Pharma Solutions

    Baxter BioPharma Solutions

    CMC Pharmaceuticals

    IDT Biologika

    Quotient Sciences
    Companies
    News Releases
    Posters
    Brochures
    Services
    Videos
    Case Study
    White Papers
    Jobs
    Contract Service Directory Companies
    Aphena Pharma Solutions

    Baxter BioPharma Solutions

    CMC Pharmaceuticals

    IDT Biologika

    Quotient Sciences
    Webinars
    Live From Shows
    • Magazine
      • Current / Back Issue
      • Features
      • Editorial
      • Columns
      • Editorial Guidelines
      • Subscribe Now
      • Advertise Now
      • Enewsletter Archive
      • Digital Edition
    • Directory
      • Companies
      • Categories
      • Corporate Capabilities
      • Add Your Company
    • Manufacturing
      • APIs
      • Aseptic Processing
      • Cleaning Validation
      • Clinical Trial Materials
      • Cytotoxics and High Potency Manufacturing
      • Equipment
      • Excipients
      • Extractables and Leachables
      • Facilities
      • Fill/Finish
      • Lyophilization
      • Parenterals
      • Process Development
      • Process Validation
      • Risk Management
      • Scale-up/ Technology Transfer
      • Solid Dosage/ Creams/ Ointments
      • cGMP Manufacture
    • Packaging
      • Capsules
      • Cold Chain Management
      • Injectables
      • Logistics
      • Serialization
      • Solid Dosage / Semi-solids
      • Supply Chain
      • Vials
    • Development
      • Analytical Services
      • Bioanalytical Services
      • Bioassay Developement
      • Biologics, Proteins, Vaccines
      • Biosimilars
      • Chemistry
      • Clinical Trials
      • Drug Delivery
      • Drug Development
      • Drug Discovery
      • Formulation Development
      • Information Technology
      • Laboratory Testing
      • Methods Development
      • Microbiology
      • Preclinical Outsourcing
      • R&D
      • Toxicology
    • Compliance
      • Filtration & Purification
      • GMPs/GCPs
      • Inspections
      • QA/QC
      • Regulatory Affairs
      • Validation
    • Top 25 Pharma & BioPharma
    • Contract Pharma Direct
    • Breaking News
    • Online Exclusives
    • Slideshows
    • Experts Opinions
    • Surveys
      • Outsourcing Survey
      • Salary Survey
    • Glossary
    • Videos
    • White Papers
    • Podcasts
    • Infographics
    • Supplier Microsite
      • Companies
      • News Releases
      • Posters
      • Brochures
      • Services
      • Videos
      • Case Study
      • White Papers
    • Contract Pharma Conference
      • Contract Pharma Conference
      • Speakers
      • Exhibitors
      • Conference Sessions
    • eBook
    • Webinars
    • Events
      • Industry Events
      • Live from Show Events
      • Webinars
    • Classifieds / Job Bank
      • Classifieds
      • Job Bank
    • About Us
      • About Us
      • Contact Us
      • Advertise With Us
      • Privacy Policy
      • Terms of Use
    Features

    Newsmakers: Lonza Pharma & Biotech

    CDMO Industry Growth Continues

    Related CONTENT
    • Outsourcing Solid Dosage Manufacturing
    • Touchlight Appoints CEO
    • Softweb Solutions
    • Proteon, Lonza Extend Contract
    • Lonza Pharma & Biotech to Expand Portsmouth Site
    Betsy Louda, Associate Editor05.08.18
    The CDMO industry has come a long way from its beginnings, when it was simply a niche service offering manufacturing capabilities that the majority of pharmaceutical companies did not have. Decades later, its growth year over year is faster than the pharmaceutical industry’s as a whole. According to a report by Ernst & Young, the CDMO industry’s annual growth rate is 6 to 7 percent, while the growth of the pharmaceutical sector as a whole is 5 to 6 percent. Outsourcing to CDMO partners is an effective strategy as pharmaceutical, biotechnology and virtual companies can access resources beyond their in-house capability to design, develop and manufacture medicines. It can also help offset potential risks of fixed costs. Lonza Pharma & Biotech has witnessed this shift firsthand. As the CDMO industry growth increases, so does the company’s capabilities, which are constantly expanding for projects with pharmaceutical companies who need their expertise and skillset. Contract Pharma spoke with Dr. Christian Dowdeswell, head of the dosage form and delivery systems business unit at Lonza Pharma & Biotech about the past, current and future trends within the exploding CDMO industry.  


    Contract Pharma: In the past decade, how has the CDMO sector evolved?

    Christian Dowdeswell:
    Largely, the sector is evolving and adapting to the changing needs of the customer. Over the last 10 years, early clinical pipelines have been driven by smaller companies that historically might have come from larger pharmaceutical companies. One trend we are seeing is that smaller companies are actually growing with their products and taking them to market, in contrast to the original model, in which perhaps they’d sell early. So that has been something for CDMOs to adapt to. These customers have different needs and perhaps more limited resources in terms of personnel. And they may also have specific gaps in their expertise. For example, they might have an innovative means to treat an unmet need but lack the technical expertise to overcome a compound’s inherent solubility issues.

    As a long-term CDMO, at Lonza we have adapted our offering. We’ve made a very conscious effort to look at these smaller companies and determine how we can really give them the support they need from getting through the early development phases all the way through to commercialization. So, I think that is one of the key trends facing CDMOs today—responding to that huge change in customer base and needs.

    CP: What is the general attitude towards outsourcing? It is going to continue to be a trend in the future?

    CD:
    Yes, absolutely. One dramatic trend over the last few years has been growth in the numbers of candidates there are in clinical phases.

    However, small companies increasingly have little motivation to put their own facilities on the ground; their primary objective is getting their drug to clinic. They have competed with other companies for investor cash, and they don’t want to have that cash tied up in assets; they want to have it working for them and solving problems until they get the drug to market. So, I fully expect to see the trend of outsourcing continue in the future.

    I think one of the other areas driving that trend is the way compounds in small molecules are developing. There are a lot more challenges around the nature of the products themselves. The small molecule APIs tend to have low solubility, increasingly have high potency, and the need for accelerated timelines to get their drug to market is commonplace. And companies are looking for people who have the expertise that can help them do so. It is one thing to have assets on the ground, but it’s a very different thing to have the right people operating them. At Lonza, our depth of expertise and broad toolkit mean we are well positioned to help people solve problems along the drug development pathway, from preclinical to launch.

    CP: What is the importance of selecting a CDMO partner that is experienced and reliable?

    CD:
    Time is something you can’t change, so when you are looking for a CDMO the number one thing you need is the guarantee that there will be no questions around quality or concerns that they’ll still be there in a year’s time. You need to have a stable and reliable CDMO. You also need to make sure that their reputation for executing and delivering what they say they will is very good.

    I think that some of these are factors that people may take for granted, when you’re in a business like ours. We refuse to compromise on quality. And I think Lonza adds value to our customers because of our reliability. If Lonza is your supplier—when it comes to due diligence and when it comes to selling your assets—it’s a recognized name, no questions asked, we will deliver.

    CP: What do you think the CDMO market outlook is for the next 10 years?

    CD:
    I think, increasingly, people are looking for value from their partners. Not just for someone to execute their plan, but to add value throughout the process. They face challenges, how do you resolve some of the problems they face? How do you get the molecule into the clinic, into the patient? How do you do it on an accelerated timeline? Timelines have come down from a standard of seven years to, for example, one that we participated in that was approved from first in human in less than 30 months, and then dosed to a patient within six hours of approval. So, accelerated timelines to get a drug to patient, especially in immuno-oncology where it is critical, have become the norm, and how CDMOs adapt to that acceleration is a critical factor in our success and future.

    CP: Since acquiring Capsugel, what type of growth have you seen, and what opportunities has it provided?

    CD:
    Capsugel has now been fully integrated into Lonza. The capsule business itself was integrated into either consumer health and nutrition or the new capsule delivery solutions business unit and the drug product services business became the dosage forms and delivery systems business unit, part of Lonza Pharma & Biotech.

    Specific to dosage forms and delivery systems, which I lead, we have acquired five sites through Capsugel that offer services including micronization, spray drying, soft gels, liquid-fill hard caps, complex tablets and modified extended release. We also added a sixth site in southern Switzerland specifically to give us dual-continent micronization capability. We look at how we can resolve our customers’ key problems. We have the right tools to address bioavailability challenges, optimize drug delivery, and offer specialized dosage forms that meet our customers’ target product profiles and commercial objectives. We work very closely with our sister business unit, which is the API development and manufacturing business, which means we offer an end to end solution from chemical intermediates through to final drug product.

    I think most of the growth to date has been from finding synergies where we’re able to offer our customers a seamless solution. For example, we produce the API, and then we support the design and development of the dosage form and manufacture clinical trial material, which we then package and distribute. We’re working with our customers to accelerate timelines, reduce complexity and just make it easier for the scientists to talk to each other as part of a single partner organization.

    CP: The Tampa, FL facility recently announced expanded encapsulation capabilities. Can you elaborate on that?

    CD:
    We added encapsulation equipment to expand our capability for powder filled capsules at commercial scale. That was largely put in with a specific project in mind, but it has broad applications for multiple customers. Many of the projects in our portfolio have started with API-in-capsule (micro-dosing) studies and are growing to launch, and we have customers looking for us to go through to commercialization with them. Those investments create a very extensive capability for us to be able to launch other products in the future. We are adding more capabilities in terms of high potency, due to be finished by May of this year. High potency is a big driver within the oncology industry. More and more products are highly potent, which makes containment an integral part of our business, something in which we’ve invested at all of our sites to make sure we’re able to respond to that in the right way. Lonza probably has the largest range of high potency capabilities in the CDMO industry, and a very long track record.

    CP: Can you provide an example of an expansion project for a specific customer?

    CD:
    Our business model helps companies get through to the commercialization phase. One of our projects already in the public domain is with a company called Clovis. We supported them by putting in place a manufacturing plant to give them extreme flexibility in ramping up quickly as demands for the product change. But it also means that facility is exclusively dedicated to them. So whenever we have customers that have specific technology requirements that are needed for their project, we’ll find a way to work with them to put that capability in place. Quite often, that means extending capabilities we have at the development scale into a commercialization scale, which is a model we have been able to repeat several times over already. 
    Related Searches
    • Clinical Trial
    • biotech
    • Pharma
    • biotechnology
    Suggested For You
    Outsourcing Solid Dosage Manufacturing Outsourcing Solid Dosage Manufacturing
    Touchlight Appoints CEO Touchlight Appoints CEO
    Softweb Solutions Softweb Solutions
    Proteon, Lonza Extend Contract Proteon, Lonza Extend Contract
    Lonza Pharma & Biotech to Expand Portsmouth Site Lonza Pharma & Biotech to Expand Portsmouth Site
    Lonza, Synpromics Enter Partnership Lonza, Synpromics Enter Partnership
    Lonza Opens Cell and Gene Therapy Mfg. Facility Lonza Opens Cell and Gene Therapy Mfg. Facility
    Orkila, Lonza Enter Capsule Delivery Solutions Pact Orkila, Lonza Enter Capsule Delivery Solutions Pact
    Solid Dosage Outsourcing Trends Solid Dosage Outsourcing Trends
    Pharma Year 2017 in Review Pharma Year 2017 in Review
    Lonza Expands Encapsulation and HPAPI Capabilities in North America Lonza Expands Encapsulation and HPAPI Capabilities in North America
    Denali Therapeutics, Lonza Pharma & Biotech Form Partnership Denali Therapeutics, Lonza Pharma & Biotech Form Partnership
    Leadership Perspective: CDMO/Sponsor Partnerships Leadership Perspective: CDMO/Sponsor Partnerships
    Lonza Lonza
    Lonza, Akouos and MEE Enter Gene Therapy Pact Lonza, Akouos and MEE Enter Gene Therapy Pact

    Related Online Exclusives

    • Cytotoxics and High Potency Manufacturing | Facilities | Solid Dosage/Creams/Ointments
      Outsourcing Solid Dosage Manufacturing

      Outsourcing Solid Dosage Manufacturing

      A Q&A with Dan Dobry, head of drug product commercial development at Lonza Pharma & Biotech.
      Tim Wright, Editor, Contract Pharma 03.12.21

    • Promotions & Moves
      Touchlight Appoints CEO

      Touchlight Appoints CEO

      Karen will work to further expand the company's contract manufacturing business, which delivers GMP materials to third parties developing COVID-19 vaccines.
      Contract Pharma Staff 10.16.20

    • Softweb Solutions

      ...
      Micheal Jury, Marketing Manager 09.23.20


    • Bio News | Bioanalytical Services | Collaborations & Alliances | Industry News | Laboratory Testing | R&D
      Proteon, Lonza Extend Contract

      Proteon, Lonza Extend Contract

      For the commercial supply of investigational vonapanitase’s active pharmaceutical ingredient
      05.08.18

    • Industry News

      Lonza Pharma & Biotech to Expand Portsmouth Site

      Will include mid-scale mammalian capacity and the addition of new cell-therapy suites
      05.07.18

    Loading, Please Wait..
    Trending
    • Gilead Sciences To Acquire MiroBio For $405M
    • BioNTech, Genmab Expand Global Strategic Oncology Collaboration
    • Amgen To Acquire ChemoCentryx For $3.7B
    • Bayer Opens New Research And Innovation Center At Kendall Square
    • Datwyler To Double Capacity At Production Ops In Pune
    Breaking News
    • BioIVT Acquires Scottish Drug-metabolizing Enzyme Manufacturer Cypex
    • Schott Creates Stand-Alone Company for its Pharma Business
    • Marken to Acquire Medical Courier Business of Cedra Express
    • Porton’s New Crystallization and Drug Product Facility
    • Thermo Fisher Expands NY Cell Culture Media Manufacturing Site
    View Breaking News >
    CURRENT ISSUE

    July/August 2022

    • Biotechnology’s Role in Improving Stroke Outcomes
    • CEO Spotlight: Marc Kikuchi
    • View More >

    Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies.
    You can obtain detailed information about the use of cookies on our website by clicking on "More information”.

    • About Us
    • Privacy Policy
    • Terms And Conditions
    • Contact Us

    follow us

    Subscribe
    Nutraceuticals World

    Latest Breaking News From Nutraceuticals World

    3i Solutions Announces New Leadership Positions
    INS Nutra Opens Gummy Manufacturing Facility
    Vital Nutrients Launches First Vegan Omega Supplement with SPMs
    Coatings World

    Latest Breaking News From Coatings World

    HGTV Home by Sherwin-Williams Announces 2023 Color Collection of the Year
    BASF to Produce More Specialty Pyrrolidones in North America
    Glasurit and FIVA Renew Their Partnership
    Medical Product Outsourcing

    Latest Breaking News From Medical Product Outsourcing

    Elizabeth Coleon Joins Withings as Chief Marketing Officer
    U.K. Strengthens Medical Device Regulations
    Fujirebio Acquires ADx NeuroSciences
    Contract Pharma

    Latest Breaking News From Contract Pharma

    BioIVT Acquires Scottish Drug-metabolizing Enzyme Manufacturer Cypex
    Schott Creates Stand-Alone Company for its Pharma Business
    Marken to Acquire Medical Courier Business of Cedra Express
    Beauty Packaging

    Latest Breaking News From Beauty Packaging

    The Body Shop Expands Partnership with Uber
    COSRX Launches Vitamin E Vitalizing Sunscreen
    Weekly Recap: Kylie Makeup Lab Controversy, Glossier Pivots to Retail and Wholesale & More
    Happi

    Latest Breaking News From Happi

    Watsons China Launches Health Care Zone Prompted by the Covid-19 Pandemic
    Earth Therapeutics Celebrates National CBD Day with Foot Balm-Enriched CBD
    Diversey Europe, LG Electronics Ink Distribution Agreement in UK/Ireland
    Ink World

    Latest Breaking News From Ink World

    Weekly Recap: Zeller+Gmelin, Epple Druckfarben Lead This Week’s News Stories
    A-Flex Label Adds Epson SurePress UV Digital Label Press
    Ball Announces 2Q 2022 Results
    Label & Narrow Web

    Latest Breaking News From Label & Narrow Web

    Eukalin acquires Adhesives Specialists
    EyeC unveils new inspection products
    Errol Moebius named VP of IST America
    Nonwovens Industry

    Latest Breaking News From Nonwovens Industry

    Weekly Recap: A New Day for Hygiene, Glatfelter Reports Q2 Results & More
    Dyper Achieves B Corp Certification
    Edgewell’s Sales Grow
    Orthopedic Design & Technology

    Latest Breaking News From Orthopedic Design & Technology

    NuVasive Inc. Reports Q2 2022 Financial Results
    Solid Growth Ahead for Carpal Tunnel Release Systems Sector
    ODT's Most-Read Stories This Week—Aug. 6
    Printed Electronics Now

    Latest Breaking News From Printed Electronics Now

    Weekly Recap: STMicroelectronics, NextFlex and onsemi Top This Week’s Stories
    Zebra Technologies Reports 2Q 2022 Results
    InnovationLab Demonstrates New PCB Production Method Based on Additive Manufacturing

    Copyright © 2022 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.

    AD BLOCKER DETECTED

    Our website is made possible by displaying online advertisements to our visitors.
    Please consider supporting us by disabling your ad blocker.


    FREE SUBSCRIPTION Already a subscriber? Login